FDA: Manufacturing Practices Slow Drug Development

Washington Drug Letter
KEYWORDS FDA / Rx
A A

The FDA believes that inadequate manufacturing processes are a main reason for slowdowns in the drug pipeline, a senior agency official says.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00